Rice Hall James & Associates LLC Takes Position in Urogen Pharma $URGN

Posted by Geri Gentry on Aug 18th, 2026

Rice Hall James & Associates LLC bought a new position in shares of Urogen Pharma (NASDAQ:URGN – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 300,650 shares of the company’s stock, valued at approximately $11,064,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. AQR Capital Management LLC raised its holdings in Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after acquiring an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the period. Jane Street Group LLC boosted its holdings in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after acquiring an additional 24,839 shares during the period. Cetera Investment Advisers acquired a new position in shares of Urogen Pharma in the second quarter valued at approximately $361,000. Finally, JPMorgan Chase & Co. grew its position in shares of Urogen Pharma by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after purchasing an additional 19,405 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Trading Up 1.9%

NASDAQ URGN opened at $49.14 on Tuesday. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $49.67. The company has a 50 day moving average of $38.96 and a 200-day moving average of $28.36. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -24.82 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million. On average, equities research analysts forecast that Urogen Pharma will post -0.2 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at approximately $4,790,520. This represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. The Goldman Sachs Group reissued a “neutral” rating and set a $44.00 price target on shares of Urogen Pharma in a report on Wednesday, July 15th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Oppenheimer lifted their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Finally, HC Wainwright upped their price target on shares of Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.38.

View Our Latest Research Report on URGN

Urogen Pharma Company Profile

(Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.